



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	337862	Liver Health Support
ARTG entry for	Medicine Listed	
Sponsor	Nutrition Care Pharmaceuticals Pty Ltd	
Postal Address	25-31 Keysborough Avenue, Keysborough, VIC, 3173 Australia	
ARTG Start Date	15/06/2020	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Liver Health Support

Product Type	Single Medicine Product	Effective Date	15/06/2020
---------------------	-------------------------	-----------------------	------------

Permitted Indications

- Antioxidant/Reduce free radicals formed in the body
- Helps reduce/decrease free radical damage to body cells
- Maintain/support general health and wellbeing
- Maintain/support healthy liver function
- Maintain/support liver health

Indication Requirements

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
------------------	------------------------

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
--------------------	---------------------



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Route of Administration Oral

Visual Identification

Active Ingredients

Bupleurum falcatum root Extract dry concentrate	20 mg
Equivalent: Bupleurum falcatum (Dry)	200 mg
Silybum marianum fruit Extract dry concentrate	214.3 mg
Equivalent: Silybum marianum (Dry)	15 g

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
colloidal anhydrous silica
croscarmellose sodium
crospovidone
hypromellose
macrogol 400
magnesium stearate
microcrystalline cellulose
stearic acid

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary